Wednesday, August 10, 2022
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Biodetection

FDA Clears New Targets for Luminex GI Pathogen Panel

by Global Biodefense Staff
October 1, 2014
E. coli bacteria

E. coli bacteria

Luminex Corporation this week announced it has received U.S. FDA clearance to add three new targets to its xTAG Gastrointestinal Pathogen Panel (GPP).

The new targets include Adenovirus 40/41, Entamoeba histolytica and Vibrio cholerae.

As the first multiplexed U.S. IVD cleared test for infectious gastroenteritis, xTAG GPP simultaneously detects 14 common viral, bacterial, and parasitic causative pathogens from a single patient sample.

The xTAG GPP panel now detects the following potential causes of gastroenteritis:

  • Campylobacter
  • Clostridium difficile toxin A/B
  • Escherichia coli (E. coli) O157
  • Enterotoxigenic E. coli (ETEC) LT/ST
  • Salmonella
  • Shigella
  • Shiga-like Toxin producing E. coli (STEC) stx 1/stx 2
  • Vibrio cholerae, cholera toxin gene (ctx)
  • Adenovirus 40/41
  • Norovirus
  • Rotavirus A
  • Cryptosporidium
  • Entamoeba histolytica
  • Giardia

By testing for greater than 90% of the causative pathogens of infectious gastroenteritis in a single test, clinicians can more quickly identify and treat the causative agent. Additionally co-infections can be more easily identified.

Simultaneous molecular testing on a single sample within a single shift also provides significant benefits to laboratories in terms of workflow and resource utilization. The ability to scale throughput by processing 96-well plates allows laboratories to easily tailor their sample processing to physician demand.

In addition, the company announced FDA has cleared the panel for use with specimens in Cary-Blair medium, a common transport medium for collection and preservation of microbiological specimens.

“We are pleased to receive clearance for this new specimen medium and these additional clinical targets which provide even more flexibility to our customers,” said Patrick J. Balthrop, president and chief executive officer of Luminex. “As laboratories are being asked to do more with less, we are continually working to deliver solutions that meet the varied needs of our customers.”

Source: Luminex press release, adapted. xTAG is a registered, protected term of Luminex.

Tags: AdenovirusC. diffCampylobacterE. coliNorovirusSalmonellaShigella

Related Posts

Bacteria That Causes Melioidosis Confirmed in Environmental Samples in Mississippi Gulf Coast
Pathogens

Bacteria That Causes Melioidosis Confirmed in Environmental Samples in Mississippi Gulf Coast

July 27, 2022
Monkeypox Transmission: Virus Detected in Saliva, Bodily Fluids
Infectious Diseases

Monkeypox Transmission: Virus Detected in Saliva, Bodily Fluids

July 17, 2022
Pathogen Crescendo: Brass, Woodwinds Section Emit Respiratory Particles
Pathogens

Pathogen Crescendo: Brass, Woodwinds Section Emit Respiratory Particles

July 16, 2022
Poxvirus Proteins Enable Early Strike on Immune Defences
Pathogens

Poxvirus Proteins Enable Early Strike on Immune Defences

July 15, 2022
Load More

Latest News

Bacteria That Causes Melioidosis Confirmed in Environmental Samples in Mississippi Gulf Coast

Bacteria That Causes Melioidosis Confirmed in Environmental Samples in Mississippi Gulf Coast

July 27, 2022
Monkeypox Transmission: Virus Detected in Saliva, Bodily Fluids

Monkeypox Transmission: Virus Detected in Saliva, Bodily Fluids

July 17, 2022
Influenza Transmission Spikes During Social Gatherings

New Universal Flu Vaccine Offers Broad Protection Against Influenza A Virus Infections

July 17, 2022
Long COVID: National Academies’ Panel Examines Long-Term Health Effects of COVID-19

Long COVID: National Academies’ Panel Examines Long-Term Health Effects of COVID-19

July 17, 2022

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC